Jaume Puig-Junoy1, Alba Ruiz Zamora2. 1. Department of Economics and Business, Pompeu Fabra University, C. Ramón Trias Fargas 25-27, Edificio Jaume I, Barcelona 08005, Spain; Centre for Research in Health and Economics (CRES-UPF), Pompeu Fabra University, Barcelona, Spain. Electronic address: jaume.puig@upf.edu. 2. Centre for Research in Health and Economics (CRES-UPF), Pompeu Fabra University, Barcelona, Spain.
Abstract
OBJECTIVE: The burden of illness that can be attributed to osteoarthritis is considerable and ever increasing. The aim of this systematic review is to analyze currently available data derived from cost-of-illness studies on the healthcare and non-healthcare costs of osteoarthritis. METHODS: PubMed, Index Medicus Español (IME), and the Spanish Database of Health Sciences [Índice Bibliográfico Español en Ciencias de la Salud (IBECS)] were searched up to the end of April 2013. This study adhered to the PRISMA guidelines. Articles were reviewed and the study quality assessed by two independent investigators with consensus resolution of discrepancies. RESULTS: We identified 39 studies that investigated the socio-economic cost of osteoarthritis. Only nine studies took a social perspective. Rather than estimating the incremental cost of osteoarthritis, nine studies estimated the total cost of treating patients with osteoarthritis without a control for comorbidity. The other 30 studies determined the incremental cost with or without a control group. Only nine studies assessed a comprehensive list of healthcare resources. The annual incremental healthcare costs of generalized osteoarthritis ranged from €705 to €19,715. The annual incremental non-healthcare-related costs of generalized osteoarthritis ranged from €432 to €11,956. CONCLUSIONS: The study concludes that the social cost of osteoarthritis could be between 0.25% and 0.50% of a country׳s GDP. This should be considered in order to foster studies that take into account both healthcare and non-healthcare costs.
OBJECTIVE: The burden of illness that can be attributed to osteoarthritis is considerable and ever increasing. The aim of this systematic review is to analyze currently available data derived from cost-of-illness studies on the healthcare and non-healthcare costs of osteoarthritis. METHODS: PubMed, Index Medicus Español (IME), and the Spanish Database of Health Sciences [Índice Bibliográfico Español en Ciencias de la Salud (IBECS)] were searched up to the end of April 2013. This study adhered to the PRISMA guidelines. Articles were reviewed and the study quality assessed by two independent investigators with consensus resolution of discrepancies. RESULTS: We identified 39 studies that investigated the socio-economic cost of osteoarthritis. Only nine studies took a social perspective. Rather than estimating the incremental cost of osteoarthritis, nine studies estimated the total cost of treating patients with osteoarthritis without a control for comorbidity. The other 30 studies determined the incremental cost with or without a control group. Only nine studies assessed a comprehensive list of healthcare resources. The annual incremental healthcare costs of generalized osteoarthritis ranged from €705 to €19,715. The annual incremental non-healthcare-related costs of generalized osteoarthritis ranged from €432 to €11,956. CONCLUSIONS: The study concludes that the social cost of osteoarthritis could be between 0.25% and 0.50% of a country׳s GDP. This should be considered in order to foster studies that take into account both healthcare and non-healthcare costs.
Authors: Cristina M Castro; Carmen Corciulo; Benjamin Friedman; Zhi Li; Samson Jacob; David Fenyo; Bruce N Cronstein Journal: Purinergic Signal Date: 2021-05-11 Impact factor: 3.765
Authors: Trevor A Lentz; Anne S Hellkamp; Nrupen A Bhavsar; Adam P Goode; Ajay Manhapra; Steven Z George Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2021-01-19
Authors: Andrew Concoff; Jeffrey Rosen; Freddie Fu; Mohit Bhandari; Kevin Boyer; Jon Karlsson; Thomas A Einhorn; Emil Schemitsch Journal: JBJS Rev Date: 2019-08
Authors: Yilun Wang; Uyen-Sa D T Nguyen; Nancy E Lane; Na Lu; Jie Wei; Guanghua Lei; Chao Zeng; Yuqing Zhang Journal: Arthritis Care Res (Hoboken) Date: 2021-03-13 Impact factor: 4.794